Thymosin Beta-4
Also known as: TB-4, Tβ4, Timbetasin
Key Facts: Thymosin Beta-4
- Category
- Healing
- FDA Status
- Not FDA Approved
- Clinical Status
- Clinical trials - Phase II/III for wound healing and dry eye
- Administration
- Subcutaneous injection, topical for eye conditions
- Typical Dose
- 2.5-5 mg 2-3x weekly
- Frequency
- 2-3x weekly
- Duration
- 4-8 weeks typical protocol
Mechanism of Action
Thymosin Beta-4 is the primary actin-sequestering protein in mammalian cells. It regulates actin polymerization, promotes cell migration, angiogenesis, and wound healing. TB-4 also has anti-inflammatory properties and promotes stem cell differentiation. The active healing region of TB-4 was isolated to create the synthetic fragment TB-500.
Research Summary
Extensive research on wound healing, cardiac repair, and tissue regeneration. Studies show TB-4 accelerates dermal wound closure and promotes corneal epithelial healing. Research in cardiac repair shows improved outcomes post-myocardial infarction in animal models. The shorter half-life means more frequent dosing compared to TB-500.
Dosing Information
Typical Dosingⓘ
Community experience
2.5-5 mg 2-3x weekly
1-10 mg per week
2-3x weekly
Full 43-amino acid protein (not TB-500 fragment). Similar uses but shorter half-life. Often confused with TB-500 in marketplace.
Research Dosingⓘ
Scientific studies
Doses observed in research studies - more frequent dosing required than TB-500 due to shorter half-life
Doses from Studies
750 mcg - 1.5 mg daily
Duration
4-8 weeks typical protocol
Administration
Subcutaneous injection, topical for eye conditions
Timing & Administration
Best Time to Take
Morning or split doses
Daily or every other day due to short half-life
Food Recommendation
With or without food
Why This Timing?
Due to short ~2 hour half-life, some protocols use multiple daily doses. Timing is flexible but consistency is important.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Injection site reactions
- ●Headache
- ●Fatigue
- ●May trigger histamine release - use caution with MCAS or histamine sensitivity
- ●Theoretical concern for cancer cell motility
- ●Contraindicated with active cancer
- ●Limited long-term safety data
References
- https://pubmed.ncbi.nlm.nih.gov/10469335/
- https://pubmed.ncbi.nlm.nih.gov/15037013/
- https://www.nature.com/articles/ncomms1041
Research This Peptide Further
Frequently Asked Questions
What does Thymosin Beta-4 do?
The full 43-amino acid protein that TB-500 is derived from. Naturally occurring in most human tissues, TB-4 has a shorter half-life (~2 hours) compared to its synthetic fragment TB-500 (~2-4 days). Often mislabeled as 'TB-500' by vendors in premixed products.
How does Thymosin Beta-4 work?
Thymosin Beta-4 is the primary actin-sequestering protein in mammalian cells. It regulates actin polymerization, promotes cell migration, angiogenesis, and wound healing. TB-4 also has anti-inflammatory properties and promotes stem cell differentiation. The active healing region of TB-4 was isolated to create the synthetic fragment TB-500.
Is Thymosin Beta-4 FDA approved?
No, Thymosin Beta-4 is not currently FDA approved. Current status: Clinical trials - Phase II/III for wound healing and dry eye
What are the side effects of Thymosin Beta-4?
Reported side effects include: Generally well-tolerated, Injection site reactions, Headache, Fatigue, May trigger histamine release - use caution with MCAS or histamine sensitivity. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Thymosin Beta-4?
Community-reported common dose: 2.5-5 mg 2-3x weekly (2-3x weekly). Range: 1-10 mg per week. Administration: Subcutaneous injection, topical for eye conditions. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Thymosin Beta-4 or used in similar applications.
TB-500
PreclinicalA synthetic 17-amino acid fragment of Thymosin Beta-4 (TB-4). Unlike TB-4, TB-500 has a longer half-life (~2-4 days vs ~2 hours) and is the active region responsible for tissue repair and cell migration. Note: Many vendors mislabel TB-4 as 'TB-500' in premixed products.
HealingBPC-157
PreclinicalA synthetic peptide derived from a protein found in human gastric juice. Known for its remarkable tissue healing properties across multiple body systems. FDA classified as Category 2 in 2023, restricting compounding.
HealingPentadecapeptide
PreclinicalThe full 15-amino acid sequence that includes BPC-157. While BPC-157 is more commonly discussed, the full pentadecapeptide has similar healing properties derived from gastric juice.
HealingZiconotide
FDAA synthetic cone snail venom peptide for severe chronic pain. The first intrathecal non-opioid analgesic FDA approved.
HealingWolverine Stack
PreclinicalThe most popular healing peptide combination, combining BPC-157 (10mg) and TB-500 (10mg). Named after the Marvel character's regenerative abilities. Used for accelerated injury recovery, joint support, and tissue repair.
Peptide BlendGlow Protocol
PreclinicalA multi-peptide skin rejuvenation blend combining BPC-157 (5mg), TB-500 (10mg), and GHK-Cu (27mg). Designed for anti-aging, skin health, and tissue repair with a focus on collagen production and cellular regeneration.
Peptide BlendWant updates on Thymosin Beta-4 research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.